期刊文献+

白细胞介素-1β在获得性耐肿瘤坏死因子相关凋亡诱导配体的肺癌H460迁移中的作用

Contribution of IL-1β to migration of lung cancer H460 cells with acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand
下载PDF
导出
摘要 目的:探讨高水平IL-1β和获得性耐肿瘤坏死因子相关凋亡诱导配体(TRAIL)的肺癌H460细胞迁移的相互作用。方法:通过RT-PCR,Western Blot和酶联免疫吸附试验检测H460-TR和野生型H4608(H460-WT)中IL-1β的水平;通过细胞迁移实验检测细胞迁移能力;通过对H460细胞施加或不施加IL-1或者IL-1R的拮抗剂检测人重组磷脂酰肌醇-3-激酶/丝苏氨酸蛋白激酶(PI3K/Akt)的迁徙范围和活性。结果:在条件培养基中的H460-TR细胞的迁徙能力和其IL-1β水平高于H460-WT细胞。肺癌H460细胞的迁徙徙能力和Akt活性和IL-1β水平一致。结论:癌症细胞中IL-1β的显著升高与H460-TR的高迁徙能力以及Akt活性是相互关联的。Akt信号是IL-1β的下游通路,IL-1β可能可以作为转移性肺癌的药物作用靶点。 Objective To determine the association of high IL-1β levels with the migration of lung cancer H460 cells with acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand(TRAIL).Methods The resistant cells were referred to as H460-TR in this study. IL-1β levels in H460-TR cells and the parent H460(H460-WT) cells were measured through RT-PCR, Western blot, and enzyme-linked immunosorbent assay. The migration capacity of the cells was determined using the migration transwell assay. The extent of migration and the activation of phosphatidyl-inositol 3-kinase / serine-threonine kinase(PI3K / Akt) were detected in H460 cells treated with or without human recombinant IL-1 or IL-1R antagonist. Results Migration capacity of H460-TR cells in the conditioned medium and its IL-1β level were higher than those of H460-WT cells.The migration capacity and Akt activation were consistent with the IL-1β level in lung cancer H460 cells.Conclusions Significantly elevated IL-1β expression in cancer cells is associated with the high migration capacity of H460-TR cells, and Akt activation. Akt signaling as the downstream pathway of IL-1β and IL-1βmay function as a therapeutic target for metastatic lung cancer.
出处 《实用医学杂志》 CAS 北大核心 2016年第7期1080-1083,共4页 The Journal of Practical Medicine
基金 广东省自然科学基金项目(编号:2015A030313469)
关键词 肺肿瘤 IL-1Β 肿瘤坏死因子相关凋亡诱导配体 AKT 迁徙能力 Lung neoplasms IL-1β TRAIL Akt Migration capacity
  • 相关文献

参考文献16

  • 1LUKENS JH, KANNEGANTI TD. Beyond canonicalinflammasomes : emerging pathways in IL-1-mediatedautoinflammatory disease [J]. Semin Immunopathol, 2014,36(5):595-609. 被引量:1
  • 2HANAHAN D, WEINBERG RA. Hallmarks of cancer: the nextgeneration [J]. Cell, 2011,144(5) :646-674. 被引量:1
  • 3DINARELLO CA,SIMON A,VANDERMEER JW. Treatinginflammation by blocking interleukin-1 in a broad spectrum ofdiseases [J]. Nat Rev Drug Discov, 2012,11(8) :633-652. 被引量:1
  • 4VORONOV E,CARMI Y,APTE RN. The role IL-1 in tumor-mediated angiogenesis [J]. Front Physiol,2014,5:114. 被引量:1
  • 5NIE L, LYHOS O, MEDDA R,et al. Endothelial-mesenchymaltransition in normal human esophageal endothelial cellscocultured with esophageal adenocarcinoma cells : role of IL-lpand TGF-^2 [J]. Am J Physiol Cell Physiol, 2014,307(9);C859-877. 被引量:1
  • 6KENNEDY GD,NUKAYA M,MORAN SM,et al. Liver TumorPromotion by 2,3,7,8 -Tetrachlorodibenzo-p-dioxin IsDependent on the Aryl Hydrocarbon Receptor and TNF/IL-1Receptors [J]. Toxicol Sci,2014,140( 1 ) : 135-143. 被引量:1
  • 7WANG X, CHEN W, ZENG W, et al. Akt-mediated eminentexpression of c-FLIP and Mcl-1 confers acquired resistance toTRAIL-induced cytotoxicity to lung cancer cells [J]. Mol CancerTher, 2008,7(5);1156-1163. 被引量:1
  • 8DINARELLO CA. Immunological and inflammatory functions ofthe interleukin-1 family [J]. Annu Rev Immunol, 2009,27:519-550. 被引量:1
  • 9DE VITA F, ORDITURA M, AURIEMMA A, et al. Serumconcentrations of proinilammatory cytokines in advanced nonsmall cell lung cancer patients [J]. JECCR, 1998,17(4) :413-417. 被引量:1
  • 10CHYCZEWSKA E, MROZ RM, KOWAL E. TNF-alpha, IL-1and IL-6 concentration in bronchoalveolar lavage fluid ( BALF)of non-small cell lung cancer (NSCLC) [J]. Rocz Akad MedBialymst, 1997,42(Suppl 1):2897-2911. 被引量:1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部